Impact of supra-cuff suction on ventilator-associated pneumonia prevention

Abstract

Critically ill patients are intubated or tracheostomized because, in most cases, these individuals require invasive mechanical ventilation. The cannulae that are used include the cuff, which can act as a reservoir for oropharyngeal secretions, predisposing to ventilator-associated pneumonia. Studies have revealed that the suction of subglottic secretions through the dorsal suction lumen above the endotracheal tube cuff delays the onset and reduces the incidence of ventilator-associated pneumonia. The aim of this review is to assess published studies regarding the significance of using suction with a supra-cuff device for the prevention of ventilator-associated pneumonia in critically ill patients treated with orotracheal intubation or tracheostomy. Therefore, by searching national and international databases, a literature review was undertaken of studies published between the years 1986 and 2011. Few results were found relating the suction of subglottic secretions to decreased duration of mechanical ventilation and length of stay in the intensive care unit. The suction of subglottic secretions is ineffective in decreasing mortality but is effective in reducing the incidence of early-onset ventilator-associated pneumonia and hospital costs. Techniques involving continuous suction of subglottic secretions may be particularly efficient in removing secretions; however, intermittent suction appears to be the least harmful method. In conclusion, cannulae with a supra-cuff suction device enable the aspiration of subglottic secretions, providing benefits to critically ill patients by reducing the incidence of ventilator-associated pneumonia and, consequently, hospital costs - with no large-scale adverse effects.

Keywords: Subglottic aspiration; Suction; Pneumonia, ventilator-associated; Intensive care

Introduction

The critically ill patient is usually dependent on mechanical ventilation enabled by prostheses, including the endotracheal tube and tracheostomy cannula. Both devices contain a cuff, which is a balloon that seals the lower airways during mechanical ventilation. The cuff should be examined every four hours, and its inflation should be maintained at an ideal pressure of 20 to 30 cmH₂O to avoid bronchoaspiration (when using reduced pressure) and tracheal wall injury (when using increased pressure).

There are two types of cuff: the high-volume, low-pressure cuff and the low-volume, high-pressure cuff. The high-volume, low-pressure cuff, which is the oldest type of cuff and is also called “red rubber,” has a small contact area
with the trachea when inflated and deforms into a circular shape. Thus, prolonged use of this device leads to ischemia and, consequently, tracheal wall injury. However, the high-volume, low-pressure cuff has a lower cost, provides stronger sealing of the trachea, and is effective against bronchoaspiration. The low-volume, high-pressure cuff is a more recently developed device that has a thin wall, which (when inflated) easily adapts to the irregular edges of the tracheal wall, preventing injuries. (5)

However, the cylindrically shaped, high-volume, low-pressure cuff does not fully protect the airways from aspiration of secretions, food, and gastric contents because it acts as a reservoir of oropharyngeal secretions, as upper airway secretions, saliva, and food that are above the cuff tend to drip from the sides of the trachea and through microchannels formed by the cuff material collapsing upon itself. (9-11) These events lead to sustained bronchoaspiration of accumulated peri-cuff materials, which is a process called microaspiration. Microaspiration, combined with bacterial colonization of the aerodigestive tract, is the main cause of ventilator-associated pneumonia (VAP). (12,13)

VAP is defined as inflammation of the lung parenchyma that is caused by infectious agents 48 to 72 hours after orotracheal intubation and the onset of mechanical ventilation. (14) VAP is typically the most frequent infection in patients admitted to the intensive care unit (ICU), representing approximately 60% of nosocomial infections and increasing the duration of hospitalization, thereby increasing hospital costs. (14) Indeed, VAP is the leading cause of morbidity and mortality among critically ill patients. (17)

Although the classification of VAP has been recently questioned, the disease is categorized as two types: early-onset (developing up to four days after the initiation of mechanical ventilation) and late-onset (developing after the fifth day of mechanical ventilation). (16,18) Early-onset VAP is usually caused by microaspiration of bacteria colonizing the oropharynx (Gram-positive cocci and Haemophilus influenzae) and usually yields a better prognosis because the disease-causing microorganisms are sensitive to antibiotics. (18) Late-onset VAP is usually caused by nosocomial organisms, including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and methicillin-resistant Acinetobacter and Staphylococcus aureus species (14) (multi-resistant microorganisms), which are associated with increased morbimortality. (18)

The concept of preventing bronchoaspiration (and thereby, VAP) is based on reducing the amount of the aspirate, among other factors. (6) A possibly preventive method is the suction of pulmonary secretions, (19) which is usually performed via an open or closed suction system. (20) In the literature, both tracheal suction systems have similar effects on the development of VAP, but these systems fail to achieve suction of secretions that accumulate in the subglottic space proximal to the cuff. (20) New endotracheal tubes and tracheostomy cannulae have been developed, which have a dorsal lumen that facilitates continuous or intermittent suction of the subglottic space, thus targeting the leakage of peri-cuff secretions. (15)

Several studies have demonstrated that aspiration of subglottic secretions (ASS) using a device with a dorsal suction lumen above the cuff of the endotracheal tube delays the onset and reduces the incidence of VAP. (15,21-25)

METHODS

The literature review was conducted using the following electronic databases: MEDLINE (Medical Literature Analysis and Retrieval System Online), PubMed (Public MEDLINE), Cochrane, SciELO (Scientific Electronic Library Online), and LILACS (Latin-American and Caribbean Health Sciences Literature Database) for the period from 1986 to 2011. The keywords used were “subglottic secretions drainage,” “subglottic aspiration,” and “ventilator-associated pneumonia”.

RESULTS

The seven relevant studies that were found are listed in table 1.

Vallés et al. (21) demonstrated that using ASS in intubated patients reduces the VAP incidence by 43.4%. However, there was no significant difference in VAP incidence between the groups given continuous ASS versus conventional aspiration, after the first week of mechanical ventilation. According to the authors, these results were possibly due to the putative decrease in the volume of oropharyngeal secretions aspirated from the interior of the bronchial tract by ASS and to the putative decrease in inoculum size. Thus, the minimum inoculum required to induce early-onset pneumonia is larger than the inoculum required to induce late-onset pneumonia. Consequently, reduction of the inoculum size might explain the delayed progression of late-onset pneumonia and reduced early-onset pneumonia in patients undergoing ASS. Finally, the authors concluded that the incidence of nosocomial pneumonia in mechanically ventilated patients can be significantly reduced using this simple method, which reduces chronic microaspiration through the cuff of endotracheal tubes.
According to Kollef et al., VAP progression is delayed in patients subjected to ASS. However, no difference was found in the overall rate of VAP between patients submitted to intermittent ASS and those who were not. The explanation of the authors for the discrepancy between their results and other studies was the small sample, the investigation of only one ICU, and the randomization method, which was based on the participants’ birthdays. However, these arguments are flawed because the study utilized a larger sample than did other studies, several of which were also conducted at only one institution and the randomization efficiently generated groups of patients without significant differences. However, Kollef et al. failed to mention having performed measurements of the cuff pressure, which could indeed explain the lack of significant differences regarding the use of ASS. Therefore, the authors conclude that ASS can be safely administered in patients undergoing heart surgery and that the occurrence of VAP can be significantly delayed in these patients via an easily applied technique.

Smulders et al. determined that VAP can be prevented by ASS in mechanically ventilated patients for more than three days and recommended incorporation of the technique into the routine care of such patients.

Dezfulian et al. found that based on the bacteriological etiology, ASS reduces the risk of VAP by approximately 50% and delays progression of VAP (compared with the control group) in addition to reducing the risk of early-onset pneumonia. Furthermore, patients submitted to ASS remain fewer days on mechanical ventilation and spend less time in the ICU. However, the length of hospital stay and mortality does not significantly differ between the groups. Thus, the authors found that ASS primarily reduces early-onset VAP and argued that it is unclear why this result did not hold for late-onset pneumonia.

Table 1 - Summary of results

| Author          | Sample number (N) | Study design                      | Type of ICU                      | Time of MV for the beginning of the evaluation of VAP | Ventilatory prosthesis | Control of cuff pressure | ASS method       | Use of prophylactic antibiotic treatment | Results                                                                 |
|-----------------|-------------------|-----------------------------------|----------------------------------|-----------------------------------------------------|------------------------|--------------------------|---------------------|------------------------------------------|-------------------------------------------------------------------------|
| Vallés et al.   | 153               | Double-blind, randomized, controlled study | Medical-surgical                 | >72 hours                                           | OTI with supra-cuff device (open versus closed dorsal suction port) | >20 mmHg, measured every four hours | Continuous     | No                            | Reduces early-onset VAP incidence by 43.3%                             |
| Kollef et al.   | 343               | Prospective clinical trial         | Cardiothoracic                    | Shortly after heart surgery                          | OTI with supra-cuff device (open versus closed dorsal suction port) | Not performed           | Intermittent  | Yes                          | Delayed VAP progression in the ASS group                              |
| Smulders et al. | 150               | Randomized clinical trial          | General                           | >72 hours                                           | OTI with supra-cuff device versus conventional OTI | Cuff inflated in an empirical manner; pressure measured every four hours | Intermittent  | No                            |                                          |
| Bouza et al.    | 690               | Prospective randomized clinical trial | Cardiothoracic                    | >48 hours                                           | OTI with supra-cuff device versus conventional OTI | 20 to 30 mmHg, measured at every shift | Continuous     | Yes                          | Reduces VAP incidence and the length of MV and ICU stay, in addition to reducing hospital costs |
| Lacherade et al.| 333               | Multicenter randomized and controlled clinical trial | Medical-surgical                 | >48 hours                                           | OTI with supra-cuff device versus conventional OTI | 20 to 30 cmH2O, measured every three hours | Intermittent  | Yes                          | Reduces early- and late-onset VAP incidence                             |
| Dezfulian et al.| 896               | Systematic meta-analysis           | Systematic                        |                                                      |                        |                          |                     |                           | Reduces the risk of early-onset VAP by 50%. Reduces the days of MV and ICU stay |
| Coffman et al.  |                    | Prospective study                 |                                   |                                                      |                        |                          |                     |                           | Reduces saliva suction. Continuous ASS appears more effective            |

ICU – intensive care unit; MV – mechanical ventilation; VAP – ventilator-associated pneumonia; ASS – aspiration of subglottic secretions; OTI – orotracheal intubation; TQT – tracheotomy.
Dezfulian et al.\(^{(23)}\) also mentioned the existence of few ASS-related complications and the occurrence of dorsal lumen obstruction in the tube with a supra-cuff device due to aspirated secretions, which caused the device to stop functioning; however, there were no adverse effects in the patient because the orotracheal tube later merely became similar to a conventional endotracheal tube. Thus, ASS appears to be effective in preventing early-onset VAP among patients who are ventilated for more than 72 hours.

Bouza et al.\(^{(15)}\) observed a significant reduction in VAP incidence in the continuous ASS group and a reduction in the density of VAP incidence. The length of stay in the ICU and the duration of mechanical ventilation are also lower in patients with continuous ASS, and there is a significant reduction in the daily dose of antibiotics in this group. Thus, continuous aspiration should be included in the protocol used to reduce the incidence and outcomes of VAP, at least in populations of patients undergoing heart surgery.

Lacherade et al.,\(^{(25)}\) in their multicenter randomized study, demonstrated that intermittent ASS reduces the incidence of VAP, including late-onset VAP without any adverse effects. The authors suggest that the reduction in the late-onset VAP incidence may have been revealed due to the large sample size, the use of prolonged mechanical ventilation (more than five days), and the low early-onset VAP incidence (use of prophylactic antibiotic treatment), as more patients could be evaluated for an extended period.

Few studies assess the effectiveness of tracheotomy cannulae combined with a supra-cuff device. Of the studies found, only Coffman et al.\(^{(24)}\) observed that aspiration of saliva is reduced by using a subglottic suction port, and continuous aspiration appears to be more effective than intermittent aspiration. These results suggest a potential decrease in the risk of aspiration in chronically ventilated patients when a tracheotomy tube with suction is used. However, the performance is expected to be similar to that of an orotracheal tube with the same device.

Several studies mention the cost of using orotracheal tubes with a supra-cuff suction device. However, Bouza et al.\(^{(35)}\) reported that ASS ensures a considerable reduction in hospital costs because the savings from purchasing antibiotics is much higher than the costs associated with an orotracheal tube with the supra-cuff device. Shorr and O’Malley\(^{(17)}\) demonstrated that tubes with the supra-cuff device may lead to significant savings if regularly used in all emergency orotracheal intubations. Although these devices are more expensive than traditional orotracheal tubes, this difference is offset by the high costs associated with VAP.

Suction of subglottic secretions provides significant clinical value. However, using bronchoscopy, Dragoumanis et al.\(^{(27)}\) observed a suction-lumen malfunction in 19 out of 40 patients (48%); 17 cases (43%) were attributed to blockage of the subglottic suction port (due to suction of the tracheal mucosa), one case of obstruction was caused by thick secretions, and one case was indeterminate. Thus, the authors argued that a negative pressure of less than 20 mmHg favors the prolapse of tracheal mucosa into the subglottic suction port, triggering local ischemia in the tracheal mucosa and exposing the patient to an elevated risk of tracheal injury.

According to Bouza et al.\(^{(15)}\), the cuff pressure should be assessed, and the suction lumen should be maintained permeable. The authors recommend instilling 10 mL of sterile water into the subglottic lumen to keep it patent. If an obstruction exists, then permeability should be restored with an air bolus through the subglottic lumen. Consequently, no continuous ASS-related complications were observed in this study. Moreover, there were no cases of lumen obstruction, as the aforementioned protocol was maintained.

In 2005, a design change in the orotracheal tube with the supra-cuff device was introduced to solve issues regarding tracheal injury and suction-lumen obstruction by thick secretions. To this end, the subglottic suction port was moved nearest the cuff, preventing suction of the tracheal mucosa, and the suction port and the lumen were extended to prevent obstruction by thick secretions. Consequently, the device had a greater external diameter than did the conventional orotracheal tube and was most likely stiffer. However, the effects of the new design on the failure rate of subglottic suction or on the occurrence of laryngeal/tracheal injuries have not yet been assessed.\(^{(11)}\)

Another issue is the mode of suction of subglottic secretions. Smulders et al.\(^{(22)}\) restricted the use of intermittent ASS because continuous suction with 100 mmHg can damage the tracheal wall.

Thus, only in the study by Kollef et al.\(^{(26)}\) there were no significant difference in VAP incidence between the groups subjected to ASS and the group undergoing conventional care. The remaining studies demonstrated a reduced VAP incidence with the use of ASS combined with cuff pressure control.\(^{(15,21-23,25)}\)

Additionally, although ASS yields few instances
of decreased duration of mechanical ventilation and ICU/hospital stay\(^{(15,23)}\) and is ineffective in decreasing mortality\(^{(15,21-23,25,26)}\), the technique efficiently reduces early-onset VAP incidence\(^{(15,21-23,25)}\) with few adverse effects being reported.\(^{(15,23,27)}\) Furthermore, ASS effectively reduces VAP-related hospital costs\(^{(15,17)}\) and is thus supported by the guidelines of three of four agencies: the Centers for Disease Control and Prevention (2004), the American Thoracic Society, and the Infectious Disease Society (2005).\(^{(28)}\) Nevertheless, cannulae combined with supra-cuff suction devices are only occasionally used, despite recommendation by these agencies’ guidelines. Gentile and Siobal\(^{(11)}\) have stated that among other aspects, the inconsistent methodologies leading to heterogeneous patient populations among studies and the lack of standard VAP diagnosis criteria could affect study results, sustaining disagreement on the strength of evidence regarding the method’s effectiveness. Another factor that should be addressed is the method of using supra-cuff devices; though intermittent suction is less harmful to the tracheal mucosa, further studies are needed to define how it should be used (i.e., the negative pressure value, suction time, and intervals). Future studies on the impact of using the supra-cuff device in tracheostomized patients are still necessary in addition to investigations assessing the effectiveness of the new design of the orotracheal tube with a supra-cuff device.

### CLOSING REMARKS

Cannulae combined with supra-cuff suction devices enable the suction of subglottic secretions, which is beneficial to critically ill patients because these devices reduce VAP incidence and, consequently, hospital costs—with no large-scale adverse effects. However, other forms of VAP prevention must be combined with use of the orotracheal tube with a supra-cuff device, as the device alone has not proven effective in reducing the duration of mechanical ventilation, ICU/hospital stays, and mortality rates.

### REFERENCES

1. Higgins DM, Maclean JC. Dysphagia in the patient with a tracheostomy: six cases of inappropriate cuff deflation or removal. Heart Lung. 1997;26(3):215-20.
2. Hixson S, Sole ML, King T. Nursing strategies to prevent ventilator-associated pneumonia. AACN Clin Issues. 1998;9(1):76-90; quiz 145-6.
3. St John RE. Advances in artificial airway management. Crit Care Nurs Clin North Am. 1999;11(1):7-17. Review.
4. Sole ML, Byers JF, Ludy JE, Zhang Y, Banta CM, Brummel K. A multisite survey of suctioning techniques and airway management practices. Am J Crit Care. 2003;12(3):220-30; quiz 231-2.
5. Spiegel JE. Endotracheal tube cuffs: design and function. Anesthesiology news: guide to airway management. 2010;51-8.
6. Barros AP, Portas JG, Queija DS. Implicações da tracheostomia na comunicação e na deglutição. Rev Bras Cir Cabeça Pescoço. 2009;38(3):202-7.
7. Blunt MC, Young PJ, Patil A, Haddock A. Gel lubrication of the tracheal tube cuff reduces pulmonary aspiration. Anesthesiology. 2001;95(2):377-81.
8. O’Neal PV, Munro CL, Grap MJ, Rausch SM. Subglottic secretion viscosity and evacuation efficiency. Biol Res Nurs. 2007;8(3):202-9.
9. Seegobin RD, van Hasselt GL. Aspiration beyond endotracheal cuffs. Can Anaesth Soc J. 1986;33(3 Pt 1):273-9.
10. Deem S, Treggiari MM. New endotracheal tubes designed to prevent ventilator-associated pneumonia: do they make a difference? Respir Care. 2010;55(8):1046-55.
11. Gentile MA, Siobal MS. Are specialized endotracheal tubes and heat-and-moisture exchangers cost-effective in preventing ventilator associated pneumonia? Resp Care. 2010;55(2):184-96; discussion 196-7.

12. Young PJ, Rollinson M, Downward G, Henderson S. Leakage of fluid past the tracheal tube cuff in a benchtop model. Br J Anaesth. 1997;78(5):557-62.

13. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388-416.

14. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165(7):867-903. Review.

15. Bouza E, Pérez MJ, Muñoz P, Rincón C, Barrio JM, Hortal J. Continuous aspiration of subglottic secretions in the prevention of ventilator-associated pneumonia in the postoperative period of major heart surgery. Chest. 2008;134(5):938-46.

16. Haringer DM. Pneumonia associada à ventilação mecânica. Pulmão RJ. 2009;Supl 2:S37-45.

17. Shorr AF, O’Malley PG. Continuous subglottic suctioning for the prevention of ventilator-associated pneumonia: potential economic implications. Chest. 2001;119(1):228-35.

18. Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med. 1998;157(2):531-9.

19. Costa D. Fisioterapia respiratória básica. São Paulo: Atheneu; 1999.

20. Lopes FM, López MF. Impacto do sistema de aspiração traqueal aberto e fechado na incidência de pneumonia associada à ventilação mecânica: revisão de literatura. Rev Bras Ter Intensiva. 2009;21(1):80-8.

21. Vallés J, Artigas A, Rello J, Bonons N, Fontanals D, Blanch L, et al. Continuous aspiration of subglottic secretions in preventing ventilator-associated pneumonia. Ann Intern Med. 1995;122(3):179-86.

22. Smulders K, van der Hoeven H, Weers-Pothof I, Vandenburgroucke-Grauls C. A randomized clinical trial of intermittent subglottic secretion drainage in patients receiving mechanical ventilation. Chest. 2002;121(3):858-62.

23. Devulian C, Shoania K, Collard HR, Kim HM, Matthay MA, Saint S. Subglottic secretion drainage for preventing ventilator-associated pneumonia: a meta-analysis. Am J Med. 2005;118(1):11-8. Review.

24. Coffman HM, Rees CJ, Sievers AE, Belafsky PC, Sacramento CA, Winston-Salem NC. Proximal suction tracheostomy tube reduces aspiration volume. Otolaryngol Head Neck Surg. 2008;138(4):441-5.

25. Lachnerade JC, De Jonghe B, Guzennec P, Debbat K, Hayon J, Monsel A, et al. Intermittent subglottic secretion drainage and ventilator-associated pneumonia: a multicenter trial. Am J Respir Crit Care Med. 2010;182(7):910-7.

26. Kollef MH, Skubas NJ, Sundt TM. A randomized clinical trial of continuous aspiration of subglottic secretions in cardiac surgery patients. Chest. 1999;116(5):1339-46.

27. Dragoumanis CK, Vretzakis GI, Papaioannou VE, Didiliis VN, Vogiatzaki TD, Pneumatikos IA. Investigating the failure to aspirate subglottic secretions with the Evac endotracheal tube. Anesth Analg. 2007;105(4):1083-5, table of contents.

28. Lorente L, Blot S, Rello J. Evidence on measures for the prevention of ventilator-associated pneumonia. Eur Respir J. 2007;30(6):1193-207.